1. Therapeutics
Goal: Treat or cure disease
Question answered: How do we intervene biologically?
What it includes
- Small molecules
- Biologics (antibodies, enzymes)
- Gene therapies
- Cell therapies (CAR-T, stem cells)
- RNA therapies
Mechanism
- Direct biological action in the patient
- Alters disease pathway, gene expression, or cell behavior
Value profile
- Highest clinical impact
- Highest regulatory burden
- Highest risk, but highest upside
IP focus
- Composition of matter
- Method of treatment
- Target/pathway claims
- Delivery mechanisms
2. Diagnostics
Goal: Detect, classify, or monitor disease
Question answered: What is happening biologically?
What it includes
- Biomarker assays
- Genetic tests
- Companion diagnostics
- Imaging agents
- Liquid biopsy
Mechanism
- Measures biological signals without treating
- Often informs therapeutic decisions
Value profile
- Faster development
- Lower regulatory risk
- Often reimbursed differently
- Critical enabler of precision medicine
IP focus
- Methods of detection
- Biomarker correlations
- Algorithms & data interpretation
- Kit and assay claims
3. Manufacturing
Goal: Make biology reproducible, scalable, and safe
Question answered: How do we reliably produce the product?
What it includes
- Bioprocessing
- Cell expansion
- Purification
- Quality control
- Supply chain and automation
Mechanism
- Controls variability in biological systems
- Translates lab innovation to commercial reality
Value profile
- Lower scientific risk
- Extremely high strategic value
- Often invisible but defensible
- Major moat for complex therapies
IP focus
- Process claims
- Systems and apparatus
- Quality control methods
- Manufacturing workflows
Summary
| Dimension | Therapeutics | Diagnostics | Manufacturing |
|---|---|---|---|
| Purpose | Treat disease | Detect disease | Enable production |
| Acts on patient? | Yes | No | No |
| Regulatory risk | Very high | Medium | Medium |
| IP strength | Very strong | Constrained | Very strong |
| Time to market | Long | Shorter | Medium |
| Competitive moat | Biology + IP | Data + adoption | Know-how + process |
Modern biotech rarely uses just one:
- Diagnostics → Therapeutics
Companion diagnostics select patients for CAR-T, gene therapy, oncology drugs - Manufacturing → Therapeutics
Cell therapies live or die by manufacturing reproducibility - Diagnostics → Manufacturing
QC assays ensure batch consistency and safety
In modern biotech, competitive advantage increasingly shifts from “what works” to “what can be made, measured, and scaled.” Many successful companies are built not on a novel molecule, but on:
- A better diagnostic stratification
- A defensible manufacturing process
- A platform that ties all three together
BioTech IP Review 
Leave a comment